2023 - Research.com Medicine in Netherlands Leader Award
Martin H. Prins mostly deals with Surgery, Internal medicine, Venous thrombosis, Thrombosis and Pulmonary embolism. His Surgery research incorporates elements of Cancer and Risk factor. His work in Internal medicine addresses subjects such as Cardiology, which are connected to disciplines such as Mortality rate.
His Venous thrombosis study combines topics in areas such as Fondaparinux Sodium, Complication, Incidence and Confidence interval. The Thrombosis study which covers Vascular disease that intersects with Radiology and Angiography. The Pulmonary embolism study combines topics in areas such as Respiratory disease, Prospective cohort study, Idraparinux and Vitamin K antagonist.
His primary areas of investigation include Internal medicine, Surgery, Thrombosis, Pulmonary embolism and Venous thrombosis. His biological study spans a wide range of topics, including Gastroenterology and Cardiology. His Surgery research incorporates themes from Confidence interval, Hazard ratio and Incidence.
Martin H. Prins interconnects Anesthesia and Heparin in the investigation of issues within Thrombosis. His studies deal with areas such as Idraparinux, Radiology and Warfarin as well as Pulmonary embolism. The study incorporates disciplines such as Cancer, Complication and Vascular disease in addition to Venous thrombosis.
His main research concerns Internal medicine, Rivaroxaban, Thrombosis, Pulmonary embolism and Randomized controlled trial. His work is dedicated to discovering how Internal medicine, Cardiology are connected with Peripheral and other disciplines. His research integrates issues of Anesthesia, Surgery, Incidence, Vitamin K antagonist and Aspirin in his study of Rivaroxaban.
Martin H. Prins works in the field of Surgery, focusing on Anticoagulant in particular. His study in Deep vein and Venous thrombosis falls within the category of Thrombosis. His research in Pulmonary embolism intersects with topics in Stroke, Fibrinolytic agent, Idraparinux and Warfarin.
His primary areas of study are Internal medicine, Rivaroxaban, Pulmonary embolism, Thrombosis and Surgery. As a part of the same scientific family, Martin H. Prins mostly works in the field of Internal medicine, focusing on Cardiology and, on occasion, Comorbidity, Radiology and Stroke. His studies in Rivaroxaban integrate themes in fields like Angiology, Anesthesia and Vitamin K antagonist.
His Pulmonary embolism study integrates concerns from other disciplines, such as First episode, Fibrinolytic agent and Warfarin. His Thrombosis research is multidisciplinary, relying on both Adverse effect and Randomized controlled trial. Martin H. Prins studies Surgery, namely Anticoagulant.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Oral rivaroxaban for symptomatic venous thromboembolism
Rupert Bauersachs;Scott D. Berkowitz;Benjamin Brenner;Harry R. Buller.
The New England Journal of Medicine (2010)
The long-term clinical course of acute deep venous thrombosis.
Paolo Prandoni;Anthonie W.A. Lensing;Alberto Cogo;Stefano Cuppini.
Annals of Internal Medicine (1996)
Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer
Agnes Y.Y. Lee;Mark N. Levine;Ross I. Baker;Chris Bowden.
The New England Journal of Medicine (2003)
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism.
Vittorio Pengo;Anthonie W. A. Lensing;Martin H. Prins;Antonio Marchiori.
The New England Journal of Medicine (2004)
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
Harry R. Büller;Hervé Décousus;Michael A. Grosso;Saskia Middeldorp.
The New England Journal of Medicine (2013)
The diagnostic odds ratio: a single indicator of test performance
Afina S. Glas;Jeroen G. Lijmer;Martin H. Prins;Gouke J. Bonsel.
Journal of Clinical Epidemiology (2003)
Antithrombotic Therapy for Venous Thromboembolic Disease : The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Harry R. Büller;Giancarlo Agnelli;Russel D. Hull;Thomas M. Hyers.
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
Paolo Prandoni;Anthonie W. A. Lensing;Andrea Piccioli;Enrico Bernardi.
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial
Bengt I Eriksson;Ola E Dahl;Nadia Rosencher;Andreas A Kurth.
The Lancet (2007)
Atrial fibrillation management: a prospective survey in ESC Member Countries The Euro Heart Survey on Atrial Fibrillation
Robby Nieuwlaat;Alessandro Capucci;A John Camm;S Bertil Olsson.
European Heart Journal (2005)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: